Blockade of LH–RH induced ovulation in immature rats by LH–RH antiserum

1976 ◽  
Vol 54 (3) ◽  
pp. 405-408 ◽  
Author(s):  
M. A. Hirsch ◽  
M. L. Givner
Keyword(s):  
Luteinizing Hormone ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Induced Ovulation ◽  
Modified Method ◽  
Immature Rats ◽  
Biological Potency ◽  
Lh Rh

An in vivo method for the determination of biological potency of luteinizing hormone -releasing hormone (LH–RH) antiserum is described. The procedure involves antiserum blockade of LH–RH induced ovulation in immature rats primed with pregnant mare's serum. A modified method for the induction of LH–RH antibodies in rabbits is also detailed.

INHIBITION BY MELATONIN OF THE PITUITARY RESPONSE TO LUTEINIZING HORMONE RELEASING HORMONE IN VIVO

1978 ◽  
Vol 76 (3) ◽  
pp. 487-491 ◽  
Author(s):  
K. YAMASHITA ◽  
M. MIENO ◽  
T. SHIMIZU ◽  
ER. YAMASHITA
Keyword(s):  
Luteinizing Hormone ◽  
Carotid Artery ◽  
Anterior Pituitary ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lh Rh ◽  
Lh Secretion

The rate of secretion of 17-oxosteroids by the testes of anaesthetized dogs in vivo was used as an index of LH secretion. Intracarotid injection of luteinizing hormone releasing hormone (LH-RH, 1, 5 or 10 μg/kg body wt) resulted in an increase in the testicular 17-oxosteroid secretion which was roughly proportional to the dose administered and which reached a maximum 60 min after the injection. Testicular output of 17-oxosteroids was unaffected by administration of melatonin (10 or 100 μg/kg body wt) into the carotid artery. When LH-RH (5 μg/kg) was injected into the carotid artery 3 h after intracarotid injection of melatonin (10 or 100 μg/kg), the testicular response to LH-RH was considerably diminished. Pretreatment with melatonin (100 μg/kg) did not alter the testicular response to human chorionic gonadotrophin (20 i.u./kg body wt) given i.v. It is concluded that melatonin may act directly on the anterior pituitary gland in dogs to inhibit the LH-RH-induced release of LH.

INHIBITORY ACTIVITY OF ANALOGUES OF LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) IN VITRO AND IN VIVO

1976 ◽  
Vol 5 (s1) ◽  
pp. s279-s289 ◽  
Author(s):  
L. FERLAND ◽  
F. LABRIE ◽  
M. SAVARY ◽  
M. BEAULIEU ◽  
D.H. COY ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Inhibitory Activity ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lh Rh

RELATIVE ACTIVITY, PLASMA ELIMINATION AND TISSUE DEGRADATION OF SYNTHETIC LUTEINIZING HORMONE RELEASING HORMONE AND CERTAIN OF ITS ANALOGUES

1979 ◽  
Vol 80 (1) ◽  
pp. 141-152 ◽  
Author(s):  
A. D. SWIFT ◽  
D. B. CRIGHTON
Keyword(s):  
Luteinizing Hormone ◽  
Pituitary Gland ◽  
Anterior Pituitary ◽  
Inverse Correlation ◽  
Anterior Pituitary Gland ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lh Rh

The abilities of three nonapeptide analogues of synthetic luteinizing hormone releasing hormone (LH-RH) to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anoestrous and cyclic ewes were examined, as were their elimination from the plasma in vivo and degradation by extracts of the hypothalamus, anterior pituitary gland, lung, kidney, liver and plasma in vitro. In all cases, comparisons were made with synthetic LH-RH. When injected i.v. into mature ewes as a single dose, the potencies of the analogues were graded and Des Gly-NH210 LH-RH ethylamide was found to be the least potent. It was not possible to demonstrate any significant increase in the potency of this analogue over LH-RH, although a trend was apparent with each parameter examined. [d-Ser(But)6] Des Gly-NH210 LH-RH ethylamide had the greatest potency. There were no differences between the responses of anoestrous ewes and those of ewes treated on day 10 of the oestrous cycle. None of the analogues had a rate of elimination from the plasma different from that of LH-RH during either the first or the second components of the biphasic disappearance curve. The incubation of LH-RH with tissue extracts showed that extracts of the hypothalamus and anterior pituitary gland degraded LH-RH to a similar extent. Both the hypothalamic and anterior pituitary gland extracts degraded more LH-RH than did lung extract, which in turn destroyed more LH-RH than did extracts of kidney or liver tissue. The degradative abilities of kidney and liver extracts did not differ from each other. Plasma failed to degrade LH-RH or the analogues. Although LH-RH was rapidly destroyed by hypothalamic extract in vitro, of the analogues, only Des Gly-NH210 LH-RH ethylamide was degraded. The anterior pituitary gland and kidney extracts failed to degrade [d-Ser6] Des Gly-NH210 LH-RH ethylamide and [d-Ser(But)6] Des Gly-NH210 LH-RH ethylamide as rapidly as LH-RH. Extracts of liver and lung were incapable of catabolizing any of the analogues. There was an inverse correlation between the LH- and FSH-releasing potency of an analogue and its rate of degradation by anterior pituitary gland extract. The slower rates of catabolism of certain analogues of LH-RH by the anterior pituitary gland may explain their increased LH- and FSH-releasing potency.

CHANGES IN RESPONSIVENESS OF DISPERSED PITUITARY CELLS TO LUTEINIZING HORMONE RELEASING HORMONE AT DIFFERENT TIMES OF THE OESTROUS CYCLE OF THE RAT

1981 ◽  
Vol 89 (1) ◽  
pp. 129-134 ◽  
Author(s):  
ALISON SPEIGHT ◽  
G. FINK
Keyword(s):  
Luteinizing Hormone ◽  
Oestrous Cycle ◽  
Female Rats ◽  
Pituitary Cells ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Close Relationship ◽  
Specific Receptors ◽  
Lh Rh

Dispersed pituitary cells obtained from female rats with regular oestrous cycles were suspended in Bio-Gel columns and perfused with pulses of luteinizing hormone releasing hormone (LH-RH). There was a close relationship between the amount of LH released and the concentration of LH-RH in the perfusate. It was not possible to elicit the priming effect of LH-RH, but the LH-response changed markedly during the oestrous cycle in a manner similar to that seen in vivo; i.e. the responses of cells prepared from rats killed at pro-oestrus were much greater than the responses of cells prepared from rats killed on other days of the cycle. A similar change in responsiveness was obtained when the columns were perfused with 60 mmol K+/1, suggesting that at least part of the increase in pituitary responsiveness that occurs at pro-oestrus is not dependent upon changes in specific receptors for LH-RH.

Evolution of Design and Achievement of Inhibitors of the Luteinizing Hormone-Releasing Hormone as Inhibitors of Ovulation

1982 ◽  
Vol 37 (2) ◽  
pp. 246-259 ◽  
Author(s):  
Karl Folkers ◽  
John Humphries ◽  
Cyril Y. Bowers
Keyword(s):  
Luteinizing Hormone ◽  
Adult Male ◽  
Subcutaneous Tissue ◽  
Female Rats ◽  
Male Rats ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lh Rh

Abstract Detailed structure-activity studies on inhibitors of the luteinizing hormone releasing hormone (LH-RH) have been described. The most potent ovulation inhibitors have substitutions in positions 1, 2, 3, and 6. Currently four basic structural requirements for potent antiovulatory activity are: a D-aromatic amino acid, such as D-Trp or D-Phe, in position 6; a D-Phe residue in position 2; substitutions in positions 1 and 3. For inhibitors based on substitutions in positions 2, 3, and 6, the substitution of a Pro, N-Me-Leu or D-Trp residue in position 3 is equally acceptable, and gives analogues which inhibit ovulation at 750 ^g/rat. For inhibitors based on substitutions in positions 1, 2, 3, and 6, D-Trp appears necessary in position 3 in order for ovulation to be inhibited at 200 μ/rat. Many analogues based on the [residue1, D-Phe2, D-Trp3, D-Trp6]-LH-RH sequence are known which inhibit ovulation at 200 μ/rat. These include those analogues having D- <Glu, Ac-Pro, N-Ac-Hyp and N-Ac-Thr in position 1. The choice between L- or Dresidues in this position is structure dependent (Ac-L-Pro > Ac-D-Pro, D- <Glu >L- <Glu, etc.). In addition, a "protected" N-terminal residue having some polar character appears to be important. Substitution of the dipeptide residue, <Glu-Pro-, into position 1 has produced a new category of potent ovulation inhibitors based on linear peptides longer than decapeptides. Continued studies on other analogues in this later class could provide more potent inhibitors by (1) utilizing new binding sites on or in the vicinity of the LH-RH receptor(s); (2) altering transportation properties; (3) producing "pro-drugs". The substitution of N-Me-Leu into position 7 was not advantageous, presumably because of the presence of bulky D-aromatic amino acids in position 6. Nonapeptide ethylamide analogues also had very low antiovulatory potencies. The analogue [chlorambucil1, Leu2, Leu3, D-Ala6]-LH-RH acted as an agonist, but also inhibited in a modified assay in vitro. Comparative assays measuring the inhibition of LH-RH, and inhibition of ovulation have emphasized other factors of importance to inhibitor design. Although all ovulation inhibitors active at 750 or 200 /μg/rat strongly inhibited in vivo, at a ratio of analogue to LH-RH of 166:1, other analogues of comparable in vitro potency have displayed a range of antiovulatory activities. Similar discrepancies have been observed in the results of in vivo LH-RH inhibition assays. The most potent ovulation inhibitors always inhibited LH-RH at 333:1 in adult male chimpanzees, and at 100:1 in adult male rats. The dissociation of the results of the LH-RH and antiovulatory assays have been rationalized in two cases. The Cpc-analogues were active in inhibiting LH-RH in rats and in chimpanzees when given i.V., but were inactive in rats when given s.c. which is the mode of administration in the antiovulatory assay. The results for inhibition of LH-RH in vivo paralleled the results for inhibition of ovulation, and raised a question as to differences in absorption of peptides though the lipid layers of subcutaneous tissue. The reduced in vivo activities of the L-Trp3 analogues in both the LH-RH and antiovulatory assays suggest an increase in enzymatic inactivation for these compounds. [D-Phe2, Pro3, D-Phe6]-LH-RH can inhibit endogenous LH-RH in the Rhesus monkey and inhibit ovulation. Infusion of [D-Phe2, Pro3, D-Trp6]-LH-RH at 375 ^ug/day for 4 days from a s.c. implanted minipump completely inhibited ovulation in cycling female rats and decreased serum LH levels in castrated rats. In contrast with LH-RH or des-Gly10- [D-Ala6]-LH-RH ethylamide the Pro3 analogue did not block uterine implantation sites of mated rats, indicating a difference in the mechanism of contraception for LH-RH agonists and inhibitors

SUPPRESSION OF THE LUTEINIZING HORMONE RELEASING EFFECT OF LUTEINIZING HORMONE RELEASING HORMONE BY ARGININE-VASOTOCIN IN IMMATURE MALE DOGS

1980 ◽  
Vol 84 (3) ◽  
pp. 449-452 ◽  
Author(s):  
K. YAMASHITA ◽  
M. MIENO ◽  
ER. YAMASHITA
Keyword(s):  
Luteinizing Hormone ◽  
Carotid Artery ◽  
Standard Dose ◽  
Isotonic Saline ◽  
Arginine Vasotocin ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Immature Male ◽  
Lh Rh

Arginine-vasotocin (0·1 or 10 ng/kg body wt) was administered into the carotid artery of anaesthetized immature male dogs 3 h before the administration of a standard dose of luteinizing hormone releasing hormone (LH-RH, 5 μg/kg body wt) into the same vessel. The rate of secretion of 17-oxosteroids by the testes in vivo served as an index of luteinizing hormone (LH) secretion. The administration of LH-RH into the carotid artery of control dogs which had been injected with isotonic saline caused a slight but definite increase in the secretion of testicular 17-oxosteroids. This effect of LH-RH on the testicular secretion of steroids was markedly reduced by pretreatment with arginine-vasotocin. However, the testicular response to the i.v. administration of human chorionic gonadotrophin (5 i.u./kg body wt) was unaffected by pretreatment with arginine-vasotocin (10 ng/kg body wt). These results indicate that in immature male dogs, arginine-vasotocin is able to inhibit the action of LH-RH by acting directly on the anterior pituitary gland.

Sign in / Sign up

Export Citation Format

Share Document